Fly News Breaks for November 13, 2019
Nov 13, 2019 | 07:38 EDT
Ladenburg analyst Matthew Kaplan said BioDelivery Sciences reported "solid" Q3 results, adding that he was impressed by the continued revenue growth of Belbuca and Symproic. He also noted that BioDelivery raised its 2019 net sales outlook and guided toward 2020 net sales of $165M-$175M. Given the new 2020 guidance and projections for continued Belbuca growth, Kaplan raised his price target on the stock to $8 from $6 and keeps a Buy rating on BioDelivery shares.
News For BDSI From the Last 2 Days
There are no results for your query BDSI